۲
Z
1
\sim
VI)
v

Applicant(s) Application No. REED, JOHN C. 09/724,425 Notice of Allowability Examiner Art Unit Jane Zara -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308. 1. This communication is responsive to <u>amendments filed 3-18-04.</u> 2. The allowed claim(s) is/are 27-30,32,33 and 35-51. 3. The drawings filed on 28 November 2000 are accepted by the Examiner. 4. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) 🗌 All b) Some* c) None of the: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)). * Certified copies not received: ___ Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient. 6. CORRECTED DRAWINGS (as "replacement sheets") must be submitted. (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) hereto or 2) to Paper No./Mail Date (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d). 7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. Attachment(s) 5. Notice of Informal Patent Application (PTO-152) 1. Notice of References Cited (PTO-892) 6. Interview Summary (PTO-413), 2. Notice of Draftperson's Patent Drawing Review (PTO-948) Paper No./Mail Date 3. Information Disclosure Statements (PTO-1449 or PTO/SB/08), 7. X Examiner's Amendment/Comment Paper No./Mail Date 4. T Examiner's Comment Regarding Requirement for Deposit 8. Examiner's Statement of Reasons for Allowance of Biological Material 9. Other ____.

JOHN L. LOGUYADER SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600 Application/Control Number: 09/724,425

Art Unit: 1635

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Irina Vainberg on or about May 20,2004.

The application has been amended as follows:

In claim 27, line 3, "a" has been replaced with -the--.

In claim 30, line 4, --wherein said splice donor sequence is GT—has been inserted before the period (".").

Claim 31 has been deleted.

In claim 33, line 4, --wherein said splice acceptor sequence is AG—has been inserted before the period (".").

Application/Control Number: 09/724,425

Art Unit: 1635

Claim 34 has been deleted.

In claim 42, line 3, the "a" preceding "translation" has been replaced with -the--.

Page 3

In claim 43, line 4, --wherein said splice donor sequence is GT—has been inserted before the period (".").

In claim 44, line 4, --wherein said splice acceptor sequence is AG—has been inserted before the period (".").

In claims 47-51, line 2, --tumor—has been inserted before "cell".

Application/Control Number: 09/724,425

Art Unit: 1635

Conclusion

Page 4

Certain papers related to this application may be submitted to Art Unit 1635 by facsimile transmission. The faxing of such papers must conform with the notices published in the Official Gazette, 1156 OG 61 (November 16, 1993) and 1157 OG 94 (December 28, 1993) (see 37 C.F.R. § 1.6(d)). The official fax telephone number for the Group is **703-872-9306**. NOTE: If Applicant *does* submit a paper by fax, the original signed copy should be retained by applicant or applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers in the Office.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to **Jane Zara** whose telephone number is **(571) 272-0765**. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, John LeGuyader, can be reached on (571) 272-0760. Any inquiry regarding this application should be directed to the patent analyst, Katrina Turner, whose telephone number is (571) 272-0564. Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

JΖ

5-20-04

JOHN / LEGUYADER / SUPERVISOR PATENT XAMINER TECHNOLOGY CENTER 1600